Goodwin Biotechnology Global Customer Value Leadership Award for Mammalian Biologics Contract Manufacturing

Frost & Sullivan Presents

Goodwin Biotechnology with the Global Customer Value Leadership Award for Mammalian Biologics Contract Manufacturing

Goodwin Biotechnology pioneered best-in-class practices for the development of complex Biopharmaceuticals and Antibody Drug Conjugates (ADCs)

LONDON — September 2, 2014 — Based on its recent analysis of the mammalian contract manufacturing services market, Frost & Sullivan recognises Goodwin Biotechnology with the 2014 Global Frost & Sullivan Award for Customer Value Leadership. Goodwin Biotechnology’s reputation as one of the most trusted providers of mammalian contract manufacturing and development services has been built on more than 20 years of experience in the bioprocess development and cGMP manufacturing of mammalian cell culture-derived monoclonal antibodies (mAbs), vaccines, and recombinant proteins, and more than 10 years pioneering the field of bioconjugation.

The Highest Quality Process Development

Goodwin Biotechnology will develop a robust and reproducible cell culture process development for the production of complex therapeutic protein drug candidates. Goodwin Biotechnology has experience with a number of cell cultivation technologies including stationary culture disposable flasks, spinners, WAVE disposable and stirred tank bioreactors. Goodwin Biotechnology offers cell culture production services for non-bioreactor projects.